Summary: Over the past 2 decades, cardiovascular (CV) disease has been recognized as one of
the most important complications of chronic kidney disease (CKD) and one of the leading
causes of death in children with advanced CKD and in young adults who developed CKD
during childhood. CV abnormalities develop early and progress during the course of
CKD in children. Characterization of the prevalence and evolution of CV disease risk
factors in progressive CKD is one of the primary aims of the Chronic Kidney Disease
in Children study. In this review, we summarize up-to-date findings from the Chronic
Kidney Disease in Children study with a focus on traditional and CKD-related CV risk
factors and early subclinical markers of cardiac and vascular structure and function.
We also discuss the effect of CV risk factors on progression of CKD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Seminars in NephrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study.Hypertension. 2008; 52: 631-637
- Ambulatory blood pressure patterns in children with chronic kidney disease.Hypertension. 2012; 60: 43-50
- Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease.Kidney Int. 2014; 85: 938-944
- Are blood pressure indices improving in children with chronic kidney disease? A period analysis.Hypertension. 2018; 71: 444-450
- Association of time-varying blood pressure with chronic kidney disease progression in children.JAMA Netw Open. 2020; 3e1921213
- Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) cohort.Am J Kidney Dis. 2015; 65: 878-888
- Twenty-four-hour ambulatory blood pressure versus clinic blood pressure measurements and risk of adverse outcomes in children with CKD.Clin J Am Soc Nephrol. 2018; 13: 422-428
- Dyslipidemia in children with chronic kidney disease.Kidney Int. 2010; 78: 1154-1163
- Change in dyslipidemia with declining glomerular filtration rate and increasing proteinuria in children with CKD.Clin J Am Soc Nephrol. 2019; 14: 1711-1718
- Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease.Clin J Am Soc Nephrol. 2011; 6: 2759-2765
- Cardiometabolic risk factors, metabolic syndrome, and chronic kidney disease progression in children.J Pediatr. 2018; 202: 163-170
- Masked hypertension associates with left ventricular hypertrophy in children with CKD.J Am Soc Nephrol. 2010; 21: 137-144
- BP control and left ventricular hypertrophy regression in children with CKD.J Am Soc Nephrol. 2014; 25: 167-174
- The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association.Pediatrics. 2004; 113: 328-333
- Adiposity, sex, and cardiovascular disease risk in children with CKD: a longitudinal study of youth enrolled in the Chronic Kidney Disease in Children (CKiD) study.Am J Kidney Dis. 2020; 76: 166-173
- Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.N Engl J Med. 2008; 359: 584-592
- Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.JAMA. 2011; 305: 2432-2439
- Fibroblast growth factor-23 and cardiovascular events in CKD.J Am Soc Nephrol. 2014; 25: 349-360
- Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.Circulation. 2009; 119: 2545-2552
- FGF23 induces left ventricular hypertrophy.J Clin Invest. 2011; 121: 4393-4408
- FGF23 and left ventricular hypertrophy in children with CKD.Clin J Am Soc Nephrol. 2018; 13: 45-52
- Cystatin C and cardiac measures in children and adolescents with CKD.Am J Kidney Dis. 2017; 69: 247-256
- Association of cystatin C with left ventricular structure and function: the Dallas Heart Study.Circ Heart Fail. 2009; 2: 98-104
- Cystatin C: an emerging biomarker in cardiovascular disease.Curr Top Med Chem. 2013; 13: 164-179
- Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure.Hypertension. 2006; 48: 830-831
- Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.Clin Chem. 2005; 51: 321-327
- Subclinical atherosclerosis: what it is, what it means and what we can do about it.Int J Clin Pract. 2008; 62: 1246-1254
- Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis.Circulation. 2007; 115: 459-467
- Carotid intima-media thickness in children with CKD: results from the CKiD study.Clin J Am Soc Nephrol. 2012; 7: 1930-1937
- Aortic dilatation in children with mild to moderate chronic kidney disease.Pediatr Nephrol. 2020; 35: 1023-1031
- Prevalence and predictors of aortic dilation as a novel cardiovascular complication in children with end-stage renal disease.Clin Nephrol. 2015; 83: 262-271
- Aortic dilatation in children with systemic hypertension.J Am Soc Hypertens. 2014; 8: 239-245
- Cachexia/protein energy wasting syndrome in CKD: causation and treatment.Semin Dial. 2019; 32: 493-499
Article info
Footnotes
Financial support: The Chronic Kidney Disease in Children Study is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, with additional funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute (grants U01DK66143, U01DK66174, U24DK082194, and U24DK066116).
Conflict of interest statement: none.
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
